Announcements
19 August 2026
Current Oncology Webinar | Canadian Breast Cancer Treatment Pathways: National Clinical Recommendations from REAL Canadian Breast Cancer Alliance, 3 September 2026
A welcome message from the Chair:
The management of breast cancer continues to evolve rapidly, driven by advances in clinical research and emerging treatment options. Staying aligned with current evidence-based standards is essential to ensuring consistent, high-quality care across Canada.
Join us for a clinician-focused webinar exploring Canadian best practices and the National Clinical Consensus Recommendations developed by REAL Canadian Breast Cancer Alliance. These annually updated guidelines are produced through a structured, multidisciplinary process that integrates national expertise and the latest clinical trial evidence to support best practices in breast cancer care delivery.
This session will provide an overview of current consensus recommendations across key disease settings, including the following:
- HER2-positive breast cancer;
- HR-positive early-stage breast cancer;
- HR-positive advanced-stage breast cancer;
- Triple-negative breast cancer.
Participants will gain a clear understanding of how these recommendations translate into clinical practice and support standardized treatment decision-making across Canadian care settings. REAL Canadian Breast Cancer Alliance continues to release annual updates aimed at strengthening alignment in care pathways and improving outcomes through evidence-informed practice.
This webinar is intended for oncologists, surgeons, radiologists, pathologists, nurse practitioners, and other healthcare professionals involved in breast cancer care.
Date: 3 September 2026, 6:00 p.m. EDT | 11:00 p.m. CEST
Webinar ID: 899 2749 6179
Register now for free!
Program:
|
Speaker/Presentation |
Time in EDT |
|
Mita Manna (Chair) Describe REAL Alliance’s purpose, including its impact on policy change |
6:00–6:10 p.m. |
|
Katarzyna J. Jerzak / Mita Manna HER2+: Apply recommendations for early and metastatic disease [Kumar et al., 2026] Neoadj pertuzumab DB05 and 11 [MM] 1L options, induction DEMETHER, brain mets [KJJ] |
6:10–6:25 p.m. |
|
Katarzyna J. Jerzak / Mita Manna HR+HER2- Early: Apply recommendations for early [Sehdev et al., 2026] Adjuvant CDK4/6i [NL] OFSET, SOFT/TEXT CCTG [MM] |
6:25–6:35 p.m. |
|
Katarzyna J. Jerzak/Nathalie Levasseur HR+HER2- Metastatic: Apply recommendations for metastatic disease [Jerzak et al., 2026] De novo – ribo / abema; what if rapid relapse INOVA120, monitoring protocol |
6:35–6:45 p.m. |
|
Nathalie Levasseur / Katarzyna J. Jerzak TNBC: Apply recommendations for early and metastatic disease [Simmons et al., 2026] KN522, CCTG MA29 / ADC TROP2 to 1L / Dato / toxicity / sequencing (Huppert on sequencing) |
6:45–7:00 p.m. |
After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations with email addresses from academic institutions will be prioritized.
Unable to attend? Register anyway and we will let you know when the recording is available for viewing.
Webinar Chair and Keynote Speakers:
- Dr. Mita Manna, Saskatoon Cancer Centre, University of Saskatchewan, Canada;
- Dr. Nathalie Levasseur, BC Cancer—Vancouver, University of British Columbia, Canada;
- Dr. Katarzyna J. Jerzak, Sunnybrook Odette Cancer Centre, University of Toronto, Canada.
